Publications by authors named "L Muul"

Article Synopsis
  • Autologous hematopoietic stem cell transplantation (HSCT) using gene-modified cells is an effective treatment for adenosine deaminase-deficient severe combined immunodeficiency (ADA-deficient SCID), particularly when combined with reduced intensity conditioning (RIC) and stopping enzyme replacement therapy (ERT).
  • In a phase II study involving 10 patients, gene-modified stem cells were successfully transplanted, showing good clinical outcomes, including normalization of blood cell activity and improved immune responses.
  • No serious complications occurred post-transplant, and many subjects remained free from further ERT, indicating strong safety and efficacy of the gene therapy approach.
View Article and Find Full Text PDF

We conducted a gene therapy trial in 10 patients with adenosine deaminase (ADA)-deficient severe combined immunodeficiency using 2 slightly different retroviral vectors for the transduction of patients' bone marrow CD34(+) cells. Four subjects were treated without pretransplantation cytoreduction and remained on ADA enzyme-replacement therapy (ERT) throughout the procedure. Only transient (months), low-level (< 0.

View Article and Find Full Text PDF

Measurement of proliferative responses of human lymphocytes is a fundamental technique for the assessment of their biological responses to various stimuli. Most simply, this involves measurement of the number of cells present in a culture before and after the addition of a stimulating agent. This unit contains several different prototype protocols to induce proliferation in lymphocytes following exposure to mitogens, antigens, allogeneic or autologous cells, or soluble factors.

View Article and Find Full Text PDF

The reasons underlying the occurrence of multiple revertant genotypes in Wiskott-Aldrich syndrome (WAS) patients remain unclear. We have identified more than 30 revertant genotypes in a C995T WAS patient having 10-15% revertant, WAS protein (WASp)-expressing circulating lymphocytes. Of 497 allospecific T-cell clones generated from the peripheral blood, 47.

View Article and Find Full Text PDF

Tpl2 (Tumor progression locus 2), also known as Cot/MAP3K8, is a hematopoietically expressed serine-threonine kinase. Tpl2 is known to have critical functions in innate immunity in regulating tumor necrosis factor-alpha, Toll-like receptor, and G protein-coupled receptor signaling; however, our understanding of its physiological role in T cells is limited. We investigated the potential roles of Tpl2 in T cells and found that it was induced by interleukin-12 in human and mouse T cells in a Stat4-dependent manner.

View Article and Find Full Text PDF